Evonik Invests €93 Million in Vancouver GMP Plant to Triple LNP Capacity
New GMP (Good Manufacturing Practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing.
Lipid Nanoparticles (LNP)
AbbVie to Acquire Capstan Therapeutics for $2 Billion
AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).
Ethris and Lonza to Develop Spray-Dried mRNA Respiratory Vaccines
Ethris and Lonza have teamed up to develop room-temperature stable, spray-dried mRNA vaccines for respiratory diseases. This collaboration aims to create mucosal delivery formulations, offering a promising new approach to combat respiratory illnesses.
Agilent to Buy Canadian CDMO Biovectra for $925 Million
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Evonik and Mainz University Partner to Commercialize Randomized PEGs
Evonik and the Johannes Gutenberg University Mainz (JGU) in Germany have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs.
CordenPharma & pHLIP Form RNA & Gene Delivery Alliance
CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
CordenPharma Expands at US Site in Colorado
CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is designed to provide innovative biotech and pharma customers with a fully integrated API to Drug Product service offering.
Wacker and CordenPharma in RNA Drugs Project
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International have launched a three-year project to accelerate the development of RNA-based drugs.
